


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.14%
+0.12%
+0.06%
-7.18%
+0.31%
DAL
Delta Air Lines
$70.96
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Outperform the market
DAL Price Performance
$64.27 (+10.41%)
$56.75 (+25.04%)
$52.52 (+35.11%)
$66.95 (+5.99%)
DAL has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Investors losing confidence

DAL overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Has a weak balance sheet

Eps growth

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
DAL Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
DAL Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
What is DAL current stock price?
What are DAL stock strengths?
What is DAL Risk Level?
What is DAL market cap and volume?
What is DAL current Stock IQ?
Should I buy DAL stock right now?
Is DAL a Strong Buy right now?
What does a 'Strong Buy' rating mean for DAL?
What does a 'Strong Sell' rating mean for DAL?
What factors influence DAL's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.14%
+0.12%
+0.06%
-7.18%
+0.31%
DAL
Delta Air Lines
Current Price
$70.96
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Outperform the market

DAL Price Performance
$64.27 (+10.41%)
$56.75 (+25.04%)
$52.52 (+35.11%)
$66.95 (+5.99%)
DAL Analysts Opinion
DAL Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Has a weak balance sheet

Eps growth

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
DAL Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
DAL Street Sentiment is extremely bullish and have positive views on the near-term outlook
DAL has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Investors losing confidence

Average key support and resistance price levels
DAL Stock IQ
DAL Latest Analysis
Secura Bio Announces Participation in Gilmartin Groups 2026 Corporate Access Event in San Francisco. BERKELEY HEIGHTS N.J. Dec. 23 2025 (GLOBE NEWSWIRE) -- Secura Bio Inc. () an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology medicines today announced that Chip Romp Chief Executive Officer. Will Brown Chief Financial Officer. and other members of the company management team will participate in Gilmartin Group'.s 2026 Corpor
Tue Dec 23, 2025
HURA: Focus on the Delta Opioid Receptor . By ASH PresentationTuHURA (NASDAQ:HURA) the American Society of Hematology (ASH) Annual Meeting and Exposition with a presentation and poster on Sunday December 7th in Orlando Florida. Updated results from the delta opioid receptor (DOR) program were provided. The content highlighted DOR expression on myeloid-derived suppressor cells (MDSCs) and the effects of DOR inhibition on tumor-associated macrophages (TAMs).The oral presentation was entitled Delta
Mon Dec 22, 2025
Wheels Up Receives NYSE Continued Listing Standard Notice. Management remains focused on multi-year business transformation including its fleet transition efficiency productivity and overhead cost reduction efforts and leveraging its partnership with Delta Air Lines to deliver premium solutions for every customer journey ATLANTA Dec. 19...
Fri Dec 19, 2025
Northeast Delta Human Services Authority Launches Light the Season Wellness Campaign to Support Communities during Winter Months. MONROE La. Dec. 18 2025 /PRNewswire/ -- Northeast Delta Human Services Authority (NEDHSA) has launched its Light the Season campaign a multi-week initiative designed to support emotional wellness educate the public about Seasonal Affective Disorder (SAD) and promote access to...
Thu Dec 18, 2025
Delta president Glen Hauenstein who helped turn airline into industry profit leader to retire in February. Deltas president Glen Hauenstein who helped turn Delta into the countrys premium-travel leader is retiring after 20 years.
Wed Dec 17, 2025
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology. Agreement underscores Norgines mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. Vir Biotechnologys chronic hepatitis delta treatment candidate has shown robust virological responses and reflects a differentiated...
Wed Dec 17, 2025
Vir Biotechnology stock rises after licensing hepatitis delta treatment.
Tue Dec 16, 2025
Early Data Shows that Coverage of Saliva-Based Screenings Drives Improved Patient Engagement and Treatment Plan Acceptance. BOSTON Dec. 10 2025 /PRNewswire/ -- A new enhanced benefit program by Delta Dental of Massachusetts (DDMA) the largest dental insurance carrier in Massachusetts focused on performance of chairside saliva-based screenings during oral exams or evaluations for periodontal (gum) disease...
Wed Dec 10, 2025
BMO Capital Initiates Coverage of Delta Air Lines (DAL) with Outperform Recommendation. Fintel reports that on December 9 2025 BMO Capital initiated coverage of Delta Air Lines (NYSE:DAL) with a Outperform recommendation. Analyst Price Forecast Suggests 7.82% Upside
Tue Dec 9, 2025
Is Delta Air Lines (DAL) Outperforming Other Transportation Stocks This Year?. Here is how Delta Air Lines (DAL) and Teekay Tankers (TNK) have performed compared to their sector so far this year.
Tue Dec 9, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.